

# PACE

## Provider Bulletin

December 14, 2010

### Prospective Drug Utilization Review (ProDUR) Criteria Additions

Effective December 14, 2010, the following maximum daily dose, duration, age and step therapy criteria have been added to the Department of Aging's Prospective Drug Utilization Review program in the following drug classes:

Drug Name/Class	Maximum Dose or Duration	Step Therapy	Diagnosis
Bupropion HBr (Aplenzin®)	348 mg per day	Prior use of bupropion tablets will be required prior to reimbursement of Aplenzin®.	
Zolpidem (Edluar®)		Claim will be stopped at the point of sale. Documentation showing the need for sublingual tablets will be required.	
Dexlansoprazole (Dexilant®)	60 mg per day		
Tapentadol (Nucynta®)	600 mg per day		
Saxagliptin (Onglyza®)	5 mg per day		

Desvenlafaxine (Pristiq®)	50 mg per day		
Milnacipran (Savella®)	200 mg per day		
Sumatriptan and naproxen (Treximet®)			Not indicated in the elderly.
Diclofenac potassium (Zipsor®)	100 mg per day		
Sitagliptin (Januvia®)		Prior to approving Januvia® cardholder will have to try and fail metformin, sulfonylurea or insulin.	
Quinine Sulfate capsules (Qualaquin®)			Approved only when prescribed to treat uncomplicated plasmodium falciprum malaria.
Teriparatide (Forteo®)	Not be reimbursed for greater than 24 months.		

Questions should be directed to Provider Services at 1-800-835-4080.